Anti-tumour necrosis factor α therapy for ankylosing spondylitis: International experience

Annals of the Rheumatic Diseases

Volumn 61, Issue SUPPL. 3, 2002, Pages

  Braun, J ^a,b   Sieper, J ^b   Breban, M ^c   Collantes Estevez, E ^d   Davis, J ^e   Inman, R ^f   Marzo Ortega, H ^g   Mielants, H ^h  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c Rheumazentrum Ruhrgebie UKBF Free University ^*  (France)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLERGIC URTICARIA; ANEMIA; ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFECTION RISK; JOINT FUNCTION; LYMPHOMA; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PANCYTOPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SEPSIS; TUBERCULOSIS; VISUAL ANALOG SCALE;

EID: 18344419026     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (62)

1. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004-12.
2. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-9.
3. Benitez Del Castillo JM, Garcia-Sanchez J, Iradier T, Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2000;14:340-3.
4. Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, et al. Serum cytokines (IL-6, TNF-α, IL-1β and IFNγ) in ankylosing spondylitis: A close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31.
5. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
6. Braun J, Xiang J, Brandt J, Maetzel H, Haibel H, Wu P, et al. Treatment of spondylarthropathies with antibodies against tumour necrosis factor α: First clinical and laboratory experiences. Ann Rheum Dis 2000;59(suppl I):i85-9.
7. Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol 1998;7:275-83.
8. De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 1989;96:339-44.
9. Mielants H, Veys EM, Cuvelier C, De Vos M. Course of gut inflammation in spondylarthropathies and therapeutic consequences. Ballieres Clin Rheumatol 1996;10:147-64.
10. May E, Marker-Hermann E, Wittig BM, Zeitz M, Meyer zum Buschenfelde KH, Duchmann R. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 2000;119:1745-55.
11. MacDonald TT, Hutchings P, Choy M, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
12. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
13. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
14. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
15. Hanauer SB, Lichtenstein GR, Columbel J-F, Mayer L, Schreiber S, Rachmilewicz D. Maintenance infliximab (Remicade) is safe, effective and steroid-sparing in Crohn's disease: Preliminary results from the Accent I trial [abstract]. Gastroenterology 2001;120:A-21.
16. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1242-6.
17. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25:1544-52.
18. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997;24:518-23.
19. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-51.
20. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
21. Antoni C, DeChant C, Ogilvie A, Kalden-Nemeth D, Kalden JR, Manger B. Successful treatment of psoriatic arthritis with infliximab in a MRI controlled study [abstract]. J Rheumatol 2000;27(suppl 59):24.
22. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psariasis resistant to treatment with methotrexate. Br J Dermatol 2001;144:587-9.
23. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 2000;356:385-90.
24. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol 2000;18:732-4.
25. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha manoclonal antibady) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
26. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
27. Lipsky P, St Clair W, Furst D, Breedveld F, Smolen J, Kalden JR, et al. 54-Week clinical and radiographic results from the ATTRACT trial: A phase III study of infliximab (Remicade®) in patients with active RA despite methotrexate [abstract]. Arthritis Rheum 1999;42:S401.
28. Finck B, Martin R, Fleischmann R, Moreland L, Schiff M, Bathon J. A phase III trial of etanercept vs. methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial) [abstract]. Arthritis Rheum 1999;42:S117.
29. Siegert S, Yin Z, Radbruch A, et al. Evidence for a different cytokine secretion pattern of peripheral blood mononuclear cells of HLA B27+ patients with ankylosing spondylitis and HLA B27+ healthy controls compared to HLA B27-negative controls [abstract]. Arthritis Rheum 1998;41:S287.
30. Canete JD, Martinez SE, Farres J, Sanmarti R, Blay M, Gomez A, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: Interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis 2000;59:263-8.
31. Yin Z, Siegert S, Neure L, Grolms M, Liu L, Eggens U, et al. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology (Oxford) 1999;38:1058-67.
32. Baeten D, Van Damme N, Van den Bosch F, Kruithof E, De Vos M, Mielants H, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis 2001;60:750-5.
33. Van Damme N, De Vos M, Baeten D, Demetter P, Mielants H, Verbruggen G, et al. Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis 2001;60:495-9.
34. Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, et al. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: Its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001;60:36-42.
35. van der Linden S, van der Heidje D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am 1998;24:663-76.
36. Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum 1999;42:2039-44.
37. Van Damme N, De Keyser F, Demetter P, Baeten D, Mielants H, Verbruggen G, et al. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clin Exp Immunol 2001;125:383-90.
38. Zou J, Rudwaleit M, Thiel A, Braun J, Sieper J. Downregulation of the non-specific and antigen-specific T cell cytokine response in ankylosing spondylitis after treatment with infliximab. Arthritis Rheum 2001;44:S236.
39. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C, et al. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondylarthropathy. Histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001;44:186-95.
40. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-2.
41. Brandt J, Haibel, H, Sieper J, Reddig J, Braun J. Infliximab treatment of severe ankylosing spondylitis: One-year followup [letter]. Arthritis Rheum 2001;44:2937.
42. Van den Bosch F, Kruithof E, Baeten D, DeKeyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: An open pilot study. Ann Rheum Dis 2000;59:428-33.
43. Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: One year follow up. Ann Rheum Dis 2002;61:207-12.
44. Mielants H. Treatment of Refractory SpA/AS with TNFα-blockers: The Belgian Experience. Lecture presented at: International Workshop on New Treatment Strategies in Ankylosing Spondylitis; 18-19 January 2002; Berlin, Germany.
45. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001;28:1605-14.
46. Collantes Estévez E. Treatment of Refractory SpA/AS with TNFα-blockers: The Spanish Experience. Lecture presented at: International Workshop on New Treatment Strategies in Ankylosing Spondylitis; 18-19 January 2002; Berlin, Germany.
47. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, et al. EFficacy of infliximab in refractory ankylosing spondylitis: Results of a six-month open-labeled study. Rheumatology (Oxford) (in press).
48. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, et al. Infliximab in ankylosing spondylitis: A prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29:959-65.
49. Braun J, Brandt J, Listing J, Zink A, Alten R, Krause A, et al. Treatment of active ankylosing spondylitis with infliximab - A double-blind, placebo-controlled multicenter trial. Lancet 2002;359:1187-93.
50. Braun J. Treatment of Refractory SpA/AS with TNFα-blockers: The German Experience. Lecture presented at: International Workshop on New Treatment Strategies in Ankylosing Spondylitis;18-19 January 2002; Berlin, Germany.
51. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-6.
52. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of entheseal pathology in resistant spondylarthropathy. Arthritis Rheum 2001;44:2112-17.
53. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002;346:1349-56.
54. Spoorenberg A, de Vlam K, van der Heijde D, de Klerk E, Dougados M, Mielants H, et al. Radiologic scoring methods in ankylosing spondylitis: Reliability and sensitivity to change over one year. J Rheumatol 1999;26:997-1002.
55. MacKay K, Mack C, Brophy S, Calin A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): A new, validated approach to disease assessment. Arthritis Rheum 1998;41:2263-70.
56. Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT. Radiological outcome in ankylosing spondylitis: Use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol 1996;35:373-6.
57. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondyloarthropathy patients. Arthritis Rheum 1994;37:1039-45.
58. Braun J, Bollow M, Sieper J. Radiology and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:697-735.
59. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
60. Modigliani R, Mary J-Y, Simon J-F, Cortot A, Soule J-C, Gendre J-P, et al. Groupe D'Etude Thérapeutique Des Affections Inflammatoires Digestives. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology 1990;98:811-18.
61. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999;50:667-71.
62. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999;116:1029-34,